Meribank Biotech Co

Meribank Biotech Co AAQS

The The AAQS of Meribank Biotech Co (4724.TWO) as of Oct 30, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Meribank Biotech Co has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Meribank Biotech Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Meribank Biotech Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2019
2.00 TWD
Jan 1, 2020
2.00 TWD
Jan 1, 2021
2.00 TWD
Jan 1, 2022
2.00 TWD
Jan 1, 2023
2.00 TWD
Jan 1, 2024
2.00 TWD
Jan 1, 2025
2.00 TWD
The Meribank Biotech Co AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Meribank Biotech Co Stock analysis

What does Meribank Biotech Co do? Meribank Biotech Co., Ltd. generates revenue by engaging in the research and development of stem cell technologies. The firm provides cord blood storage and application services for hematopoietic stem cells, as well as placenta and umbilical cord storage and application services for mesenchymal stem cells. Additionally, the company offers peripheral blood stem cell storage service and application service to its clients. The business model extends to the promotion of stem cell transplantation application and the development of new stem cell processing technology and storage application services. Meribank Biotech Co., Ltd. also develops allogeneic umbilical cord mesenchymal stem cell manufacturing and therapeutic applications, creating value through these specialized biotechnological offerings. Meribank Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meribank Biotech Co stock

The AAQS of Meribank Biotech Co is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Meribank Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Meribank Biotech Co

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Meribank Biotech Co